December 18, 2015
Not intended for U.S. and UK Media

Bayer Receives Positive CHMP Opinion for BAY 81-8973 for the Treatment of Hemophilia A in Patients in EU

Berlin, December 18, 2015 - The European Committee for Medicinal Products for
Human Use (CHMP) has recommended BAY 81-8973, Bayer's new recombinant factor
VIII compound, for approval in the EU for the treatment and prophylaxis of
bleeding in patients with hemophilia A for all age groups. BAY 81-8973 is an
unmodified full-length recombinant factor VIII compound that, in clinicals
trials, has demonstrated control of bleeds and protection from bleeds in
hemophilia A patients when used prophylactically two or three times per week.

The final decision of the European Commission on the marketing authorization is
expected in the coming weeks. Hemophilia affects approximately 400,000 people
around the world and is characterized by prolonged or spontaneous bleeding,
especially into the muscles, joints or internal organs.

"Bayer is highly committed to the hemophilia community, exemplified best by our
latest development BAY 81-8973, as well as by our long-acting recombinant
factor VIII pipeline candidate BAY 94-9027", said Dr. Joerg Moeller, Member of
the Bayer HealthCare Executive Committee and Head of Global Development. "In
addition, we are also pursuing different early stage treatment approaches in
hemophilia including an anti-TFPI-antibody."

The positive CHMP recommendation is based on results from the LEOPOLD
(Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical
trials, which evaluated BAY 81-8973 in children, adolescents and adults using
both, prophylaxis dosing regimens and on-demand treatment.

Bayer has submitted marketing applications for BAY 81-8973 in the US and
several other countries and is pursuing regulatory approvals worldwide.

Bayer is committed to delivering science for a better life by advancing a
portfolio of innovative treatments. Hematology at Bayer includes an approved
treatment for hemophilia A and numerous compounds in various stages of
development for hemophilia, sickle cell anemia, and other blood and bleeding
disorders. Together, these compounds reflect the company's commitment to
research and development for these indications, prioritizing specific targets
for intervention with the potential to improve the way that rare blood and
bleeding disorders are treated.


The LEOPOLD Clinical Development Program consists of three multinational
clinical trials designed to evaluate the pharmacokinetics, efficacy, and safety
of BAY 81-8973 in subjects with severe hemophilia A (<1% FVIII:C).

LEOPOLD I is an open-label, cross-over Phase III study in males aged 12-65
years. The objectives were to demonstrate the efficacy and safety of BAY
81-8973 when used as prophylaxis, for the treatment of bleeding episodes, and
for maintaining hemostasis during surgery. In LEOPOLD I, investigators assigned
subjects to either the two- or three-times-weekly dosing regimens based on each
patient's phenotype, prior bleeding history and other factors.

LEOPOLD II is a randomized, cross-over, open-label trial also in male subjects
aged 12 to 65 years. In this Phase III study, 80 subjects were randomized to
receive BAY 81-8973 either as a low-dose prophylaxis regimen (20-30 IU/kg;
n=28) twice-per-week, high-dose prophylaxis (30-40 IU/kg; n=31)
three-times-per-week, or on-demand (n=21). The primary objective was to
demonstrate the superiority of prophylaxis versus on-demand therapy, with the
primary endpoint being bleeding frequency at 12 months.

LEOPOLD Kids is an open-label, non-randomized Phase III study. Part A is
designed to evaluate the efficacy and safety of BAY 81-8973 for prophylaxis,
treatment of bleeds, and surgical management in previously treated children
<=12 years of age with twice or three times per week or every other day
prophylaxis regimens. Part B of the study, which involves previously untreated
patients (PUPs), is ongoing.
About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care and agriculture. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of around EUR 20.0 billion (2014), is one of the world's leading,
innovative companies in the healthcare and medical products industry and is
based in Leverkusen, Germany. The company combines the global activities of the
Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer
HealthCare's aim is to discover, develop, manufacture and market products that
will improve human and animal health worldwide. Bayer HealthCare has a global
workforce of 60,700 employees (Dec 31, 2014) and is represented in more than
100 countries. More information is available at

Our online press service is just a click away:
Follow us on Facebook:
Follow us on Twitter:

Find more information at

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or